全文获取类型
收费全文 | 2243篇 |
免费 | 127篇 |
国内免费 | 343篇 |
专业分类
林业 | 8篇 |
农学 | 35篇 |
基础科学 | 1篇 |
19篇 | |
综合类 | 572篇 |
农作物 | 4篇 |
水产渔业 | 178篇 |
畜牧兽医 | 1872篇 |
园艺 | 17篇 |
植物保护 | 7篇 |
出版年
2024年 | 3篇 |
2023年 | 17篇 |
2022年 | 48篇 |
2021年 | 58篇 |
2020年 | 74篇 |
2019年 | 87篇 |
2018年 | 44篇 |
2017年 | 50篇 |
2016年 | 83篇 |
2015年 | 79篇 |
2014年 | 131篇 |
2013年 | 103篇 |
2012年 | 177篇 |
2011年 | 192篇 |
2010年 | 117篇 |
2009年 | 141篇 |
2008年 | 138篇 |
2007年 | 203篇 |
2006年 | 158篇 |
2005年 | 132篇 |
2004年 | 113篇 |
2003年 | 80篇 |
2002年 | 74篇 |
2001年 | 76篇 |
2000年 | 73篇 |
1999年 | 37篇 |
1998年 | 35篇 |
1997年 | 39篇 |
1996年 | 17篇 |
1995年 | 27篇 |
1994年 | 26篇 |
1993年 | 14篇 |
1992年 | 17篇 |
1991年 | 11篇 |
1990年 | 8篇 |
1989年 | 10篇 |
1987年 | 4篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1979年 | 6篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1973年 | 1篇 |
1956年 | 2篇 |
排序方式: 共有2713条查询结果,搜索用时 15 毫秒
1.
旨在对制备的甘露糖修饰的壳聚糖聚乳酸-羟基乙酸共聚物[poly (D,L-lactide-co-glycolide),PLGA]纳米微球作为口蹄疫病毒(foot-and-mouth disease virus,FMDV)核酸疫苗递送载体进行评价。采用西佛碱反应和元素分析制备具有一定取代度的甘露糖修饰的壳聚糖衍生物(mannose modified chitosan,MCS),然后,经双重乳化挥发法制备得到甘露糖修饰的壳聚糖PLGA纳米微球(MCS-PLGA-NPs)。采用纳米粒径仪检测MCS-PLGA-NPs粒径分布和表面电势(zeta)、扫描电镜考察其形态、琼脂糖凝胶电泳观察其对质粒的吸附和吸附质粒后抵抗核酸酶降解能力、CCK-8法检测MCS-PLGA-NPs的细胞毒性、激光共聚焦观察巨噬细胞对MCS-PLGA-NPs-质粒DNA复合物的摄取、荧光显微镜和Western blot验证MCS-PLGA-NPs加载质粒DNA在细胞中的表达。元素分析结果表明,成功制备了取代度为5%~10%的MCS。纳米粒径测定和扫描电镜结果表明,MCS-PLGA-NPs的zeta为正值、粒径分布均匀且形态规则呈球形。琼脂糖凝胶电泳结果显示,MCS-PLGA-NPs吸附质粒的能力随着其质量的增加而增强并且可以在一定程度上抵抗核酸酶降解质粒DNA。在细胞毒性试验中,不同浓度的MCS-PLGA-NPs与RAW264.7细胞共孵育24 h后,细胞存活率仍在85%以上。在细胞摄取试验中,用激光共聚焦显微镜可以明显观察到质粒DNA结合到纳米微球表面被RAW264.7细胞摄取。荧光显微镜和Western blot试验证明MCS-PLGA-NPs加载质粒DNA可以在细胞中进行表达。综上表明,本研究成功制备了MCS以及具有递送核酸疫苗能力的MCS-PLGA-NPs,为FMDV核酸疫苗的递送研究提供了新的方向和见解,也为该递送载体携带特定抗原靶向抗原递呈细胞表面甘露糖受体以及应用于动物免疫的研究奠定基础。 相似文献
2.
3.
AIM: To investigate the expression and roles of family with sequence similarity 3, member C (FAM3C) in oral squamous-cell carcinoma cells. METHODS: The mRNA and protein expression levels of FAM3C in dysplastic oral keratinocyte (DOK) and oral squamous-cell carcinoma WSU-HN6 cells were detected by RT-qPCR and Western blot. The WSU-HN6 cells were treated with siFAM3C or FAM3C antibody. After 24, 48 and 72 h, the viability of WSU-HN6 cells was measured by CCK-8 assay, and the activation of protein kinase B (Akt) was detected by Western blot. Adenovirus was used to mediate over-expression of FAM3C in the DOK cells. The DOK cell viability was measured by CCK-8 assay after adenovirus infection for 24, 48 and 72 h, and the activation of Akt was detected by Western blot. RESULTS: Compared with the DOK cells, the mRNA and protein levels of FAM3C were significantly increased in the WSU-HN6 cells (P<0.05). The viability of WSU-HN6 cells transfected with siFAM3C was significantly inhibited at 48 h and 72 h (P<0.05). siFAM3C treatment inhibited the activation of Akt (P<0.05). FAM3C antibody treatment also suppressed the viability of the WSU-HN6 cells at 48 h and 72 h and the activation of Akt (P<0.05). Over-expression of FAM3C in the DOK cells promoted the cell viability at 48 h and 72 h and activated Akt (P<0.05). CONCLUSION: FAM3C might promote oral squamous-cell carcinoma cell growth by activating Akt. 相似文献
4.
Protective efficacy of an H5/H7 trivalent inactivated vaccine produced from Re-11, Re-12, and H7-Re2 strains against challenge with different H5 and H7 viruses in chickens 下载免费PDF全文
ZENG Xian-ying CHEN Xiao-han MA Shu-jie WU Jiao-jiao BAO Hong-mei PAN Shu-xin LIU Yan-jing DENG Guo-hua SHI Jian-zhong CHEN Pu-cheng JIANG Yong-ping LI Yan-bing HU Jing-lei LU Tong MAO Sheng-gang GUO Xing-fu LIU Jing-li TIAN Guo-bin CHEN Hua-lan 《农业科学学报》2020,19(9):2294-2300
We developed an H5/H7 trivalent inactivated vaccine by using Re-11, Re-12, and H7-Re2 vaccine seed viruses, which were generated by reverse genetics and derived their HA genes from A/duck/Guizhou/S4184/2017(H5 N6)(DK/GZ/S4184/17)(a clade 2.3.4.4 d virus), A/chicken/Liaoning/SD007/2017(H5 N1)(CK/LN/SD007/17)(a clade 2.3.2.1 d virus), and A/chicken/Guangxi/SD098/2017(H7 N9)(CK/GX/SD098/17), respectively. The protective efficacy of this novel vaccine and that of the recently used H5/H7 bivalent inactivated vaccine against different H5 and H7 N9 viruses was evaluated in chickens. We found that the H5/H7 bivalent vaccine provided solid protection against the H7 N9 virus CK/GX/SD098/17, but only 50–60% protection against different H5 viruses. In contrast, the novel H5/H7 trivalent vaccine provided complete protection against the H5 and H7 viruses tested. Our study underscores the importance of timely updating of vaccines for avian influenza control. 相似文献
5.
余金霞 《畜牧兽医科学(电子版)》2021,(4):17-18
牛口蹄疫是传染性疾病,为研究青海省峰堆乡口蹄疫疫苗的免疫效果,于2018—2019年对该乡的7个村开展牛口蹄疫疫苗免疫效果调查,共调查牛634头,7个村总体的口蹄疫合格率为100.00%和97.56%,最低合格率为81.63%和88.63%。为更好地控制该类疾病发生流行,提升免疫效果,该文探讨口蹄疫疫苗免疫失败原因,并制定了相应的预防措施。 相似文献
6.
Goatpox (GTP), sheeppox (SPP) and lumpy skin disease (LSD) are three severe diseases of goat, sheep and cattle. Their typical clinical symptoms are characterized by vesicles, papules, nodules, pustules and scabs on animal skins. The GTP, SPP and LSD are caused by goatpox virus (GTPV), sheeppox virus (SPPV) and lumpy skin disease virus (LSDV), respectively, all of which belong to the genus Capripoxvirus in the family Poxviridae. Several capripoxvirus (CaPV) isolates have been virulently attenuated through serial passaging in vitro for production of live vaccines. CaPV-based vector systems have been broadly used to construct recombinant vaccines for delivering foreign antigens, many of which have been demonstrated to induce effective immune protections. Homologous recombination is the most commonly used method for constructing recombinant CaPVs. Here, we described a methodology for generation of recombinant CaPVs by the homologous recombination, and further reviewed CaPV-vectored vaccines for delivering foreign antigens. 相似文献
7.
8.
Denicia Atujona Yucong Huang Zhiwen Wang Jichang Jian Shuanghu Cai 《Aquaculture Research》2019,50(9):2628-2634
Despite significant improvements in aquaculture to compensate wild catch, disease organisms have thrived in limiting its national and global potential. Using antibiotics, in a bid to remedy the havoc, has given rise to complications, attracting attention to disease prevention by immune enhancement against diseases. Grouper production has been inhibited for the threats of bacterial infection, particularly of Vibrio origin. Considering the rise in vibriosis cases, improved vaccines are necessary; moreover, recombinant vaccines, the choice for trial in the present experiment have been effective and more specific in improving immunity. The current work deals with grouper immune system enhancement with a recombinant vaccine developed from VirB11 gene in Vibrio harveyi. VirB11 was cloned in V. harveyi for recombinant vaccine development against vibriosis in orange‐spotted grouper (Epinephelus coioides). As indicated by the results, recombinant VirB11 protein showed effectiveness in conferring protection against vibriosis with observable specific antibody response in enzyme‐linked immunosorbent assay (ELISA) analysis; a significant increase (p < 0.05) in antibody levels was observed after a week and after 8 weeks post‐vaccination. From the weeks post‐vaccination, log2 (antibody titres) in the sera of vaccinated groups reached a peak of 14.2 at week 5 in the vaccinated group in comparison with a peak of approximately 5 and 2 in adjuvant and PBS controls. As indicated by the challenge results, 90% relative survival was observed in vaccinated group and 13% relative survival in control group I (adjuvant control). The cumulative performance of protein concludes VirB11 commendable for recombinant vaccine development. 相似文献
9.
10.